a public good project by the
Synthesis
Company
of California

© 2026

Klaus Baumann | doi.page

0 works0 citations0 h-index

Klaus Baumann

University of Zurich(CH)

Publications by Year

Research Areas

Ovarian cancer diagnosis and treatment, Endometrial and Cervical Cancer Treatments, Cervical Cancer and HPV Research, PARP inhibition in cancer therapy, Hormonal Regulation and Hypertension

Most-Cited Works

→ Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer(2019)2,180 cited
→ Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study(2009)688 cited
→ Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer(2014)328 cited
→ Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group(2013)242 cited
→ Adjuvant Therapy in Lymph Node–Positive Vulvar Cancer: The AGO-CaRE-1 Study(2015)227 cited
→ Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production(1998)184 cited

→ Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer(2011)

183 cited

→ Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial(2020)158 cited

→ Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO—The MIMOSA Study(2013)143 cited

→ Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes(2017)140 cited